Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide + formoterol is a fixed-dose combination inhaled medication used for the management of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta-2 adrenergic agonist (LABA) that relaxes airway smooth muscle to improve airflow. This combination helps control symptoms such as wheezing, shortness of breath, coughing, and chest tightness in patients whose conditions are not adequately managed with other therapies or who require multiple daily medications. It is not intended for acute asthma attacks or sudden bronchospasm[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + formoterol (AstraZeneca).